文献速递系统性红斑狼疮

系统性红斑狼疮症状聚类及其与患者报告结局和治疗的相关性:真实世界数据分析

Systemic Lupus Erythematosus Symptom Clusters and Their Association With Patient-Reported Outcomes and Treatment: Analysis of Real-World Data.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-04-22

基于美国及5个欧洲国家1376例SLE患者的横断面调查,通过主成分因子分析和潜在类别聚类分析识别出4个症状严重度集群(极轻、轻、中、重)。随集群严重度增加,医生报告的症状负担、器官受累、疾病活动度、 flares数量及患者报告的健康状况、疲劳、工作生产力损害、焦虑/抑郁和情感影响均增加(P<0.0001)。糖皮质激素和免疫抑制剂使用增加而抗疟药使用减少,所有集群中生物制剂使用<20%,>15%未使用生物制剂的患者被医生认为符合治疗条件,医患治疗满意度随严重度增加而下降(P<0.0001)。

要点

  • 基于39个症状识别出4个SLE集群,严重度越高器官受累和患者负担越重。
  • 生物制剂使用率在所有集群中均低于20%,高疾病活动度患者存在未满足治疗需求。
  • 医患治疗满意度随集群严重度增加而下降。

核心结论

  • SLE患者可按症状严重度分为4个集群,集群严重度越高,器官受累、患者报告负担和治疗不满意度越重,高疾病活动度患者存在未满足的有效治疗需求。

研究设计与样本

  • 横断面真实世界调查(Adelphi Real World Lupus Disease Specific Programme),覆盖美国和5个欧洲国家,纳入1376例连续就诊的成人SLE患者,风湿科医生提供数据。
  • 采用主成分因子分析将常见并发症状降维为因子,再以因子为协变量进行潜在类别聚类分析识别患者集群。

主要发现

  • 基于39个体征/症状识别出4个集群:极轻、轻、中、重。
  • 随集群严重度增加,医生报告的症状负担、器官受累、疾病活动度和flares数量均增加(P<0.0001)。
  • 随集群严重度增加,患者报告的健康状况、疲劳、工作生产力损害、焦虑/抑郁和情感影响均增加(P<0.0001)。
  • 随集群严重度增加,糖皮质激素和免疫抑制剂使用增加而抗疟药使用减少。
  • 所有集群中生物制剂使用<20%,>15%未使用生物制剂的患者被医生认为符合治疗条件;医患治疗满意度随严重度增加而下降(P<0.0001)。

关键数值与推荐

  • 共纳入1376例患者,87%为女性,74%为白人。
  • 基于39个 signs/symptoms 识别出4个集群(very mild、mild、moderate、severe)。
  • 医生报告结局和患者报告结局随集群严重度增加的差异均P<0.0001。
  • 所有集群中<20%患者接受生物制剂;>15%未接受生物制剂的患者被医生认为符合治疗条件。
  • 医患治疗满意度随集群严重度增加而下降(P<0.0001)。

临床怎么用

  • 临床可依据症状集群严重度识别高负担SLE患者,并关注其器官受累和患者报告结局的恶化。
  • 对高疾病活动度集群应评估生物制剂治疗资格,因该人群中生物制剂使用率低且存在未满足需求。
  • 治疗满意度随严重度下降,需优化高严重度集群的治疗策略以改善医患满意度。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify discrete clusters of systemic lupus erythematosus (SLE) patients based on symptoms and investigate differences across clusters. METHODS: Data were collected in the US and 5 European countries via the Adelphi Real World Lupus Disease Specific Programme, a cross-sectional survey. Rheumatologists provided data for 5 consecutively consulting adult patients with SLE, who were invited to participate. Identified SLE symptoms were reduced to factors based on commonly concurrent symptoms, using principal-component factor analysis. Factors were used as covariates in a latent-class cluster analysis to identify discrete patient clusters. Patient-reported outcomes and physician-reported data were compared across clusters. RESULTS: Among 1,376 patients, 87% were female and 74% were White. We identified 4 patient clusters (very mild, mild, moderate, and severe) based on 39 signs/symptoms. Physician-reported symptom burden, organ involvement, disease activity, and the number of flares increased with increasing cluster severity (P < 0.0001). Patient-reported impact (health status, fatigue, work productivity impairment, anxiety/depression, and emotional impact) increased with increasing cluster severity (P < 0.0001). Glucocorticoid and immunosuppressant use increased, and antimalarial use decreased, with increasing cluster severity. In all clusters, <20% of patients received biologics; >15% of patients not receiving biologics were considered eligible for treatment by their physician. The proportion of physicians and patients satisfied with treatment decreased with increasing cluster severity (P < 0.0001). CONCLUSION: Our large, international, real-world survey of SLE patients and physicians demonstrated strong associations between increased impairment, organ involvement, and humanistic burden in SLE, highlighting an unmet need for effective treatment options in patients with high disease activity.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Touma Z, Hoskin B, Atkinson C, et al. Systemic Lupus Erythematosus Symptom Clusters and Their Association With Patient-Reported Outcomes and Treatment: Analysis of Real-World Data. Arthritis Care Res (Hoboken). 2022. PMID: 33345456. doi:10.1002/acr.24546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。